Rejuvel Bio-Sciences (NUUU) Inactive 10-Q19 Nov 132013 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2013	Nov. 10, 2013
Document And Entity Information	'	'
Entity Registrant Name	'Technology Applications International Corp	'
Entity Central Index Key	'0001481427	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	117,448,000
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2013	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets	'	'
Cash and cash equivalents	$4,580	$120,697
Accounts receivable	0	0
Inventories	121,490	125,408
Deposits	60,000	50,000
Other current assets	1,909	3,814
Total current assets	187,979	299,919
Trademarks, net	1,968	2,049
Machinery and equipment, net	10,483	13,462
Total assets	200,430	315,430
Liabilities	'	'
Accounts payable and accrued expenses	313,209	193,894
Advances from affiliate	163,159	157,843
Loan from affiliate	77,401	88,880
Convertible debentures (net of debt discount of $168,973 and $134,292, respectively)	150,027	65,708
Derivative liability	440,494	276,000
Short-term advances	5,000	0
Total current liabilities	1,149,290	782,325
Total liabilities	1,149,290	782,325
Shareholders' deficit	'	'
Preferred stock, par value, $0.001 per share, 50,000,000 shares authorized, none issued or outstanding	0	0
Common stock, par value $0.001 par value, 300,000,000 shares authorized, 117,248,000 and 117,248,000 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively.	117,248	117,248
Additional paid in capital	505,220	505,220
Accumulated deficit	-1,571,328	-1,089,363
Total shareholders' deficit	-948,860	-466,895
Total liabilities and shareholders' deficit	$200,430	$315,430

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	50,000,000	50,000,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	117,248,000	117,248,000
Common stock, shares outstanding	117,248,000	117,248,000
Discount on convertible debentures	$168,973	$134,292

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended		47 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'	'
Revenues	$4,313	$1,837	$35,841	$3,287	$45,320
Cost of revenues	-1,219	827	6,039	1,148	10,533
Gross profit	5,532	1,010	29,802	2,139	34,787
Expenses	'	'	'	'	'
General and administrative	77,635	165,045	365,336	563,294	1,303,370
Loss From Operation	-72,103	-164,035	-335,534	-561,155	-1,268,583
Other income (expense)	'	'	'	'	'
Gain (loss) on derivative valuation	-8,250	0	85,150	0	162,350
Interest expense	-74,050	0	-231,581	0	-465,095
Total other income (expense)	-82,300	0	-146,431	0	-302,745
Net loss	($154,403)	($164,035)	($481,965)	($561,155)	($1,571,328)
Loss per share	'	'	'	'	'
Basic and diluted	$0	$0	$0	$0	'
Weighted average number of shares	'	'	'	'	'
Basic and diluted	117,248,000	117,248,000	117,248,000	117,204,686	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended		47 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Cash flows from operating activities	'	'	'
Net loss	($481,965)	($561,155)	($1,571,328)
Adjustments to reconcile net income to net cash used in operating activities:	'	'	'
Imputed interest on beneficial conversion feature of warrants attached to convertible debenture	0	-38,382	0
Loss (Gain) on derivative valuation	-85,150	0	-162,350
Amortization of discount on convertible debentures	214,963	0	433,871
Depreciation and amortization	3,060	3,136	11,372
Shares issued for cancellation of debt	0	0	101,800
Shares issued for services rendered	0	0	11,318
Change in current assets and current liabilities:	'	'	'
(Increase) in accounts receivable	0	-198	0
(Increase) decrease in inventory	3,918	-190,324	-121,490
(Increase) decrease in deposits	-10,000	0	-60,000
(Increase) decrease in other current assets	1,905	-190	-1,909
Increase in accounts payable and accrued expenses	117,315	134,620	313,209
Increase (decrease) in other current liabilities	2,000	-387	0
Net cash used in operating activities	-233,954	-576,116	-1,147,307
Cash flows from investing activities	'	'	'
Purchase of equipment	0	0	-21,553
Increase in trademarks	0	-470	-2,170
Net cash used in investing activities	0	-470	-23,723
Cash flows from financing activities	'	'	'
Proceeds from short-term advances	5,000	0	5,000
Advances from (to) affiliate, net	5,316	-90,450	264,959
Proceeds from loan from affiliate	0	125,000	125,000
Repayment of loan from affiliate	-11,479	-16,000	-47,599
Proceeds from issuance of convertible debenture	119,000	31,944	319,000
Proceeds from issuance of common stock	0	465,055	509,250
Net cash provided by financing activities	117,837	515,549	1,175,610
Net change in cash and cash equivalents	-117,837	-515,549	4,580
Cash and cash equivalents, beginning balance	120,697	174,363	0
Cash and cash equivalents, ending balance	4,580	113,326	4,580
Supplemental disclosure of cash flow information	'	'	'
Income taxes paid	0	0	0
Interest paid	0	0	0
Non-cash transactions affecting Operating, Investing and Financing activities	'	'	'
Deposit converted to convertible debenture	0	100,000	100,000
Issuance of common stock - shareholder note payable	0	0	101,800
Issuance of common stock for services	$0	$0	$11,318

1_Nature_of_Operations_and_Sum

1. Nature of Operations and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
1. Nature of Operations and Basis of Presentation	'
	1. Nature of Operations and Basis of Presentation

	Nature of Operations

	Technology Applications International Corporation (“Technology”) was incorporated on October 14, 2009 under the laws of Florida. Renuell Int’l, Inc. and NueEarth, Inc., Technology’s wholly owned subsidiaries and Technology, collectively, are referred to here-in as the “Company”, a development stage company. The Company is engaged in developing market entry technology products and services into early and mainstream technology products and services. Through our subsidiaries, we are focused on developing and manufacturing a line of technologically advanced skin care products and providing environmental management solutions that use electron particle accelerator technology.

	Principles of Consolidation

	The consolidated financial statements include the accounts of Technology Applications International Corporation and its wholly owned subsidiaries, Renuell Int’l, Inc. and NueEarth, Inc. All significant inter-company accounts and transactions have been eliminated in consolidation.

	Basis of Presentation and Going Concern Considerations

	The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2013.

	For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.

	The accompanying financial statements have been presented on the basis that it is a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs. The Company’s ability to continue as a going concern is highly dependent upon management’s ability to increase near-term operating cash flows and obtain additional working capital through the issuance of debt and or equity. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

	These consolidated financial statements present the financial condition, and results of operations and cash flows of the operating companies.

	Development Stage Risk

	Since its inception, the Company has been dependent upon the receipt of capital investment to fund its operating activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plans will be successfully executed. The Company’s ability to execute its business plans is dependent on its ability to obtain additional debt and equity financing and achieving a profitable level of operations. There can be no assurance that sufficient financing will be obtained or that we will achieve a profitable level of operations.

	The Company has minimal revenues generated from operations due to the sale of sample products. Accordingly, the Company’s activities have been accounted for as those of a “Development Stage Enterprise” as set forth in Accounting Standards Codification (“ASC”) 915 “Development Stage Entities”. Among the disclosures required are that the Company’s financial statements be identified as those of a development stage company and that the statements of operations, shareholders’ equity / (deficit) and cash flows disclose activity since the date of the Company’s inception.

2_Inventories

2. Inventories	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
2. Inventories	'
	2. Inventories

	Inventories are stated at the lower of cost or market value. The Company reduces the value of its inventories to market value when the value is believed to be less than the cost of the item.

		September	December
		30, 2013	31, 2012

	Raw materials	$ -	$ -
	Work-in-process	-	-
	Finished goods	121,490	125,408

	Total Inventories	$121,490	$125,408


	No reserves for inventory have been deemed necessary at September 30, 2013.

3_Machinery_and_Equipment

3. Machinery and Equipment	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
3. Machinery and Equipment	'
	3. Machinery and Equipment

	Machinery and equipment are recorded at cost. Expenditures for maintenance and repairs are charged to earnings as incurred whereas additions, renewals and betterments are capitalized. When machinery and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of machinery and equipment is provided using the straight-line method over the assets estimated useful lives of approximately 5 to 7 years. Leasehold improvements, if any, are amortized on a straight-line basis over the term of the lease or the estimated useful lives, whichever is shorter.

	Machinery and equipment, as of September 30, 2013 and December 31, 2012, consisted of the following:

		Estimated Useful Lives	September	31-Dec-12
			30, 2013

	Computer Equipment	3 Years	$ 4,162	$ 4,162
	Machinery and equipment	5 Years	3,418	3,418
	Furniture and fixtures	7 Years	14,073	14,073
	Accumulated depreciation		-11,170	-8,191

			$ 10,483	$ 13,462


	Depreciation expense for the nine-month periods ended September 30, 2013 and 2012 were $2,979 and $3,061, respectively. Depreciation expense for the three-month periods ended September 30, 2013 and 2012 were $993 and $1,020, respectively.

4_Convertible_Debenture

4. Convertible Debenture	9 Months Ended
4. Convertible Debenture	Sep. 30, 2013
Notes to Financial Statements	'
4. Convertible Debenture	'
	4. Convertible Debenture

	During December 2011, the Company received $100,000 as a deposit for entering into a distribution agreement. On March 22, 2012, the Company converted the $100,000 deposit into a convertible debenture. The convertible debenture bears interest at a rate of five-percent (5%) per annum and is payable March 21, 2014. At the Holder’s option, principle and unpaid accrued interest shall be convertible into common stock at a rate of $0.50 per share. In

	addition to the common stock, the Holder shall receive warrants to purchase an equal number of shares of common stock exercisable at $1.00 per share. These warrants expire at the earlier of 180 days after the common stock commences quotation on the OTC Bulletin Board or one-year from exercise.

	On September 25, 2012, the Company issued a $100,000 convertible debenture. The convertible debenture bears interest at a rate of five-percent (5%) per annum and is payable September 20, 2013. At the Holder’s option, principle and unpaid accrued interest shall be convertible into common stock at a rate of $0.50 per share. In addition to the common stock, the Holder shall receive warrants to purchase an equal number of shares of common stock exercisable at $1.00 per share. These warrants expire at the earlier of 180 days after the common stock commences quotation on the OTC Bulletin Board or one-year from exercise. This convertible debenture extended 360 days on September 21, 2013

	On May 23, May 31, June 10, July 29, August 14, and September 25, 2013, the Company issued a $10,000, $10,000, $25,000, $4,000, $50,000 and $20,000 convertible debentures, respectively. The convertible debentures bear interest at a rate of ten-percent (10%) per annum and is payable May 18, May 26, June 5, 2014, July 24, august 9, September 20, 2014, respectively. At the Holder’s option, principle and unpaid accrued interest shall be convertible into common stock at a rate of $0.50 per share. In addition to the common stock, the Holder shall receive warrants to purchase an equal number of shares of common stock exercisable at $1.00 per share. These warrants expire at the earlier of 180 days after the common stock commences quotation on the OTC Bulletin Board or one-year from exercise.

	The Compound derivative comprises certain derivative features embedded in the host convertible debenture contracts including the conversion feature and warrants both of which contain anti-dilution protections. These instruments were combined into one compound derivative and bifurcated from the host instrument at fair value. The Company applied the Black-Scholes Merton valuation technique to fair value these derivatives because this technique embodies all of the assumptions necessary to fair value these compound derivative instruments.

	Since the derivative financial instruments are required to be recorded, both initially, and subsequently, at fair value, there were insufficient proceeds to allocate any amount to the convertible debentures and, accordingly, it has no carrying value on the date of inception. Additionally, proceeds were insufficient to record the fair values of the derivative financial instruments, resulting in initial interest expense of $283,844. It should be noted that the derivative instruments will be adjusted to fair value at each reporting date. As the Company does not have historical volatility data for its own stock, the expected volatility was based upon the Company’s peer group in the industry in which it does business. Fair values are highly influenced by the trading stock price and volatility of the peer group, changes in our credit risk and market interest rates.

	The company amortizes the discount on the convertible debentures resulting from the initial allocation over the term of the convertible debt instruments using the effective method. Amortization expense arising from this method for the nine months ended September 30, 2013 and 2012 was approximately $214,963 and $0, respectively. These amounts have been included as a component of interest expense.

5_Capital_Stock

5. Capital Stock	9 Months Ended
5. Capital Stock	Sep. 30, 2013
Notes to Financial Statements	'
5. Capital Stock	'
	5. Capital Stock

	Common Stock

	On August 26, 2010, the Company issued 100,000 shares of its common stock to purchase equipment.

	On October 20, 2011, the Company issued 101,800,000 shares of its common stock as payment for cancellation of debt for part of the amount due to its related party.

	On October 28, 2011, the Company issued 5,727,000 shares of its common stock to a consultant as payment for services rendered.

	On November 8, 2011, the Company issued 5,591,000 shares of its common stock to a consultant as payment for services rendered.

	During November and December 2011, the Company issued 236,000 shares of its common stock through a private placement to several investors for total cash consideration of $118,000.

	During January and February 2012, the Company issued 794,000 shares of its common stock through a private placement for total cash consideration of $397,000.

	Stock Purchase Warrants

	In conjunction with the Private Placement Memorandum dated October 28, 2011, the Company is offering up to 10,000 Units. Each Unit consists of 1,000 shares of common stock priced at $0.50 per share and one Class A Warrant to purchase 1,000 shares of common stock with an exercise price of $1.00 per share. These warrants expire on the earlier of (i) 180 days after the common stock commences quotation on the OTC Bulletin Board or (ii) one year after the date of issuance.

	Warrants to purchase up to 1,030,000 shares of common stock were issued in accordance with the Private Placement Memorandum stated above. As these warrants were issued as part of a unit sold, there has been no value assigned to them. As of September 30, 2013, each of these warrants has expired.

	In conjunction with the Private Placement Memorandum dated February 13, 2013, the Company is offering up to 3,000,000 units. Each unit consists of 1 share of common stock priced at $1.00 and one Class A Warrant to purchase 1 share of common stock with an exercise price of $1.50 per share. These warrants expire on the earlier of (i) 180 days after the common stock commences quotation on the OTC Bulletin Board or (ii) one year after the date of issuance. No issuances have been sold from this offering as of September 30, 2013.

6_Fair_Value_Measurements

6. Fair Value Measurements	9 Months Ended
6. Fair Value Measurements	Sep. 30, 2013
Notes to Financial Statements	'
6. Fair Value Measurements	'
	6. Fair Value Measurements

	On a recurring basis, we measure certain financial assets and liabilities based upon the fair value hierarchy. The following table presents information about the Company’s liabilities measured at fair value as of September 30, 2013 and December 31, 2012:

		Level 1	Level 2	Level 3	Fair Value at September 30, 2013
	Liabilities
	Derivative Liability	-	-	$ 440,494	$ 440,494


		Level 1	Level 2	Level 3	Fair Value at December 31, 2012
	Liabilities
	Derivative Liability	-	-	$ 276,000	$ 276,000


	The fair value changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), relate solely to the derivative liability as follows:

	Balance as of December 31, 2011	$ -
	Derivative liability recorded	353,200
	Fair value adjustment	(77,200)
	Balance at December 31, 2012	276,000
	Derivative liability recorded	399,244
	Fair value adjustment	-234,750
	Balance at September 30, 2013	$ 440,949

7_Related_Parties

7. Related Parties	9 Months Ended
7. Related Parties	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Related Parties	'
	7. Related Parties

	An affiliate of the Company, an entity owned by the Company’s president, has been funding operations of the Company by making payments directly to third parties or advancing monies to the Company. These amounts bear no interest and are payable on demand. Amounts due to the affiliate at September 30, 2013 and 2012 are approximately $163,000 and $158,000, respectively.

	During September 2012, the Company borrowed $125,000 from an affiliate. The loan bears interest at 10% per annum and is unsecured and payable upon demand. The Company has paid $47,600 towards the loan amount. The outstanding balance at September 30, 2013 and December 31, 2012 is $77,401 and $88,880, respectively.

8_Significant_Agreement

8. Significant Agreement	9 Months Ended
8. Significant Agreement	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
8. Significant Agreement	'
	8. Significant Agreement

	On September 30, 2013, the Company and its wholly-owned subsidiary Renuell Int’l, Inc., Florida corporations (the “Company”) entered into a partially exclusive Co-License Agreement (the “License Agreement”) by and amongst the National Aeronautics and Space Administration, an agency of the United States (“N.A.S.A.”) and the Administrators of the Tulane Educational Fund (“Tulane University”) for the use of U.S. Patent No. 6,730,498 B1, an invention entitled “Production of Functional Proteins: Balance of Shear Stress and Gravity,” which was issued on May 4, 2004 (the “Patent”). The company currently uses the Patent process to develop our anti-aging skin creams and shampoos. The License Agreement permits the Company to use the Patent as well as the name N.A.S.A., with its products, as per the terms of the License Agreement.

	In consideration of the grant of the License Agreement, the Company will pay a 2% royalty to both N.A.S.A. and Tulane University on the gross sales of any royalty-base products, for a total of a 4% royalty. The License agreement further requires the Company to remit to N.A.S.A. and Tulane University a non-refundable license fee in the amount of Five Thousand Dollars ($5,000) each (for a total of $10,000) upon the execution of the License Agreement. The Company also agrees to pay N.A.S.A. and Tulane University a minimum royalty of Five Thousand Dollars ($5,000) each (for a total of $10,000), at the end of each accounting period (“Accounting Period”). The Accounting Period shall begin on the date of the License Agreement and end on December 31, the first Accounting Period payment will be prorated. Subsequent Accounting Periods begin on January 1, and end on December 31, of each calendar year.

	The License Agreement requires that the Company achieve a practical application of the Patent within three months from the commencement date of the License Agreement. Once a practical application is achieved the term of the agreement shall be equal to the unexpired term of the last patent to be in effect of the patent(s) encompassed under the Patent. The Company further agrees that any products using the Patent process shall be substantially manufactured in the United States.

9_Subsequent_Events

9. Subsequent Events	9 Months Ended
9. Subsequent Events	Sep. 30, 2013
Subsequent Events [Abstract]	'
9. Subsequent Events	'
	9. Subsequent Events

	Pursuant to Accounting Standards Codification 855-10, the Company has evaluated all events or transactions that have occurred from July 1, 2013 through the filing with the SEC.

	On October 2, 2013, the holders of convertible notes converted a total of $50,000 of principal and interest into 100,000 shares of our common stock.

	On October 4, 2013, the Company terminated its distribution agreement (“Distribution Agreement”) by and between the Company and Regenetech, Inc., a Texas corporation, pursuant to the termination clauses contained within the Distribution Agreement. Regenetech, Inc., was in a material breach of contract of the Distribution Agreement, because Regenetech, Inc., failed to upkeep its license requirements with N.A.S.A. and the Tulane University in order to maintain the license in good standing. Due to the material breach of contract by Regenetech, Inc., the termination of the Distribution Agreement does not contain any early termination penalties to the Company.

1_Nature_of_Operations_and_Sum1

1. Nature of Operations and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Notes to Financial Statements	'
Nature of Operations	'
	Nature of Operations

	Technology Applications International Corporation (formerly Raj Ventures, Inc.) (“Technology”) was incorporated on October 14, 2009 under the laws of Florida. Renuell Int’l, Inc. and NueEarth, Inc., Technology’s wholly owned subsidiaries and Technology, collectively, are referred to here-in as the “Company”, a development stage company. The Company is engaged in developing market entry technology products and services into early and mainstream technology products and services. Through our subsidiaries, we are focused on developing and manufacturing a line of technologically advanced skin care products and providing environmental management solutions that use electron particle accelerator technology.

Principles of Consolidation	'
	Principles of Consolidation

	The consolidated financial statements include the accounts of Technology Applications International Corporation and its wholly owned subsidiaries, Renuell Int’l, Inc. and NueEarth, Inc. All significant inter-company accounts and transactions have been eliminated in consolidation.

Basis of Presentation and Going Concern Considerations	'
	Basis of Presentation and Going Concern Considerations

	The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2013 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2013.

	For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.

	The accompanying financial statements have been presented on the basis that it is a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs. The Company’s ability to continue as a going concern is highly dependent upon management’s ability to increase near-term operating cash flows and obtain additional working capital through the issuance of debt and or equity. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

	These consolidated financial statements present the financial condition, and results of operations and cash flows of the operating companies.

Development Stage Risk	'
	Development Stage Risk

	Since its inception, the Company has been dependent upon the receipt of capital investment to fund its operating activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plans will be successfully executed. The Company’s ability to execute its business plans is dependent on its ability to obtain additional debt and equity financing and achieving a profitable level of operations. There can be no assurance that sufficient financing will be obtained or that we will achieve a profitable level of operations.

	The Company has minimal revenues generated from operations due to the sale of sample products. Accordingly, the Company’s activities have been accounted for as those of a “Development Stage Enterprise” as set forth in Accounting Standards Codification (“ASC”) 915 “Development Stage Entities”. Among the disclosures required are that the Company’s financial statements be identified as those of a development stage company and that the statements of operations, shareholders’ equity / (deficit) and cash flows disclose activity since the date of the Company’s inception.

2_Inventories_Tables

2. Inventories (Tables)	9 Months Ended
2. Inventories (Tables)	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
		September	December
		30, 2013	31, 2012

	Raw materials	$ -	$ -
	Work-in-process	-	-
	Finished goods	121,490	125,408

	Total Inventories	$121,490	$125,408

3_Machinery_and_Equipment_Tabl

3. Machinery and Equipment (Tables)	9 Months Ended
3. Machinery and Equipment (Tables)	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Machinery and equipment	'
		Estimated Useful Lives	September	31-Dec-12
		Estimated Useful Lives	30, 2013	31-Dec-12

	Computer Equipment	3 Years	$ 4,162	$ 4,162
	Machinery and equipment	5 Years	3,418	3,418
	Furniture and fixtures	7 Years	14,073	14,073
	Accumulated depreciation		-11,170	-8,191

			$ 10,483	$ 13,462

6_Fair_Value_Measurements_Tabl

6. Fair Value Measurements (Tables)	9 Months Ended
6. Fair Value Measurements (Tables)	Sep. 30, 2013
Notes to Financial Statements	'
Derivative Liabilities	'
		Level 1	Level 2	Level 3	Fair Value at September 30, 2013
	Liabilities
	Derivative Liability	-	-	$ 440,494	$ 440,494


		Level 1	Level 2	Level 3	Fair Value at December 31, 2012
	Liabilities
	Derivative Liability	-	-	$ 276,000	$ 276,000

Derivative Liability Fair Value Adjustment	'
	Balance as of December 31, 2011	$ -
	Derivative liability recorded	353,200
	Fair value adjustment	(77,200)
	Balance at December 31, 2012	276,000
	Derivative liability recorded	399,244
	Fair value adjustment	-234,750
	Balance at September 30, 2013	$ 440,949

2_Inventories_Details

2. Inventories (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Inventory Disclosure [Abstract]	'	'
Raw materials	$0	$0
Work-in-process	0	0
Finished goods	121,490	125,408
Total Inventories	$121,490	$125,408

3_Machinery_and_Equipment_Deta

3. Machinery and Equipment (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012
3. Machinery and Equipment (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Computer Equipment	Machinery and Equipment	Furniture and Fixtures
Computer Equipment	$4,162	$4,162	'	'	'
Machinery and equipment	3,418	3,418	'	'	'
Furniture and fixtures	14,073	14,073	'	'	'
Accumulated depreciation	-11,170	-8,191	'	'	'
Machinery and equipment, net	$10,483	$13,462	'	'	'
Estimated useful lives	'	'	'3 years	'5 years	'7 years

3_Machinery_and_Equipment_Deta1

3. Machinery and Equipment (Details Narrative) (USD $)	3 Months Ended		9 Months Ended
3. Machinery and Equipment (Details Narrative) (USD $)	Sep. 30, 2013	Jun. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Property, Plant and Equipment [Abstract]	'	'	'	'
Depreciation expense	$993	$1,020	$2,979	$3,061

4_Convertible_Debenture_Detail

4. Convertible Debenture (Details Narrative) (USD $)

1 Months Ended

9 Months Ended

47 Months Ended

Dec. 31, 2011

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 25, 2013

Aug. 14, 2013

Jul. 29, 2013

Jun. 10, 2013

31-May-13

23-May-13

Feb. 13, 2013

Sep. 25, 2012

Mar. 22, 2012

Oct. 28, 2011

Notes to Financial Statements

Deposit on distribution agreeement

$100,000

Deposit converted into convertible debenture

100,000

Convertible debenture issued

20,000

50,000

4,000

25,000

10,000

100,000

Interest rate of convertible debenture, per annum

10.00%

5.00%

Maturity date of convertible debenture

20-Sep-14

9-Aug-14

24-Jul-14

5-Jun-14

26-May-14

18-May-14

20-Sep-13

21-Mar-14

Debt conversion to common stock rate

$0.50

Number of warrants offered per share issued from converted debt

Warrants exercisable for common stock, price per share

Expiration of warrants, years

'1 year

Expiration of warrants, days after common stock is quoted on OTCBB

'180 days

Initial Interest expense

283,844

Amortization expense

$214,963

$433,871

5_Capital_Stock_Details_Narrat

5. Capital Stock (Details Narrative) (USD $)

2 Months Ended

24 Months Ended

Feb. 29, 2012

Dec. 31, 2011

Dec. 31, 2012

Sep. 30, 2013

Sep. 25, 2013

Aug. 14, 2013

Jul. 29, 2013

Jun. 10, 2013

31-May-13

23-May-13

Feb. 13, 2013

Sep. 25, 2012

Mar. 22, 2012

Nov. 08, 2011

Oct. 28, 2011

Oct. 20, 2011

Aug. 26, 2010

Units

Notes to Financial Statements

Common stock issued for cash, shares, duration

794,000

236,000

Common stock issued for cash, value, duration

$397,000

$118,000

Common stock issued for equipment, shares

100,000

Common stock issued for debt, shares

101,800,000

Common stock issued for services, shares

5,591,000

5,727,000

Private placement units offered

'3,000,000

'10000

Shares per unit

1,000

Common stock price per share

$0.50

Warrants per unit

Class A Warrants, shares per warrant

1,000

Exercise price per share in warrant

$1.50

Expiration of warrants, years

'1 year

Expiration of warrants, days after common stock is quoted on OTCBB

'180 days

Number of untis sold in February 13, 2013 private offering

Number of warrant shares issued, shares

1,030,000

Number of warrant shares expired, shares

1,030,000

6_Derivative_Liabilities_Detai

6. Derivative Liabilities (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Derivative liability	$440,494	$276,000
Level 1	'	'
Derivative liability	0	0
Level 2	'	'
Derivative liability	0	0
Level 3	'	'
Derivative liability	440,494	276,000
Fair Value	'	'
Derivative liability	$440,494	$276,000

6_Derivative_Liability_Fair_Va

6. Derivative Liability Fair Value Adjustment (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012
	Sep. 30, 2013	Dec. 31, 2012	Derivative Liability	Derivative Liability	Derivative Liability	Derivative Liability Recorded	Derivative Liability Recorded	Fair Value Adjustment	Fair Value Adjustment
Derivative liability	$440,494	$276,000	$440,949	$276,000	$0	'	'	'	'
Derivative liability recorded	'	'	'	'	'	399,244	353,200	'	'
Fair value adjustment	'	'	'	'	'	'	'	($234,750)	($77,200)

7_Related_Parties_Details_Narr

7. Related Parties (Details Narrative) (USD $)	1 Months Ended	9 Months Ended
7. Related Parties (Details Narrative) (USD $)	Jun. 30, 2012	Mar. 31, 2013	Sep. 30, 2013	Dec. 31, 2012
Related Party Transactions [Abstract]	'	'	'	'
Due to affiliates	'	'	$163,000	$158,000
Loan from affiliate	125,000	'	'	'
Interest rate on loan from affiliate	10.00%	'	'	'
Repayments on loan from affiliate	'	47,600	'	'
Oustanding balance on loan from affiliate	'	'	$77,401	$88,880

8_Significant_Agreement_Detail

8. Significant Agreement (Details Narrative) (USD $)	Sep. 30, 2013
Co-License Agreement on Patent	'
Royalty percent paid to NASA per the patent license	20.00%
Royalty percent paid to Tulane University per the patent license	20.00%
Total royalty due on patent license agreement	4.00%
Minimum royalty due to NASA per calendar year accounting period	$5,000
Minimum royalty due to Tulane University per calendar year accounting period	5,000
Total royalty due per calendar year accounting period	$10,000
Months to achieve practical application of patent required by license	'3 months

9_Subsequent_Events_Details_Na

9. Subsequent Events (Details Narrative) (USD $)	Oct. 02, 2013
Subsequent Events [Abstract]	'
Notes converted to shares of common stock	$50,000
Shares of common stock issued from conversion of notes	100,000